122 related articles for article (PubMed ID: 31894316)
1. Anti‑proliferative effect of cardamonin on mTOR inhibitor‑resistant cancer cells.
Niu P; Li J; Chen H; Zhu Y; Zhou J; Shi D
Mol Med Rep; 2020 Mar; 21(3):1399-1407. PubMed ID: 31894316
[TBL] [Abstract][Full Text] [Related]
2. Autophagy induced by cardamonin is associated with mTORC1 inhibition in SKOV3 cells.
Shi D; Niu P; Heng X; Chen L; Zhu Y; Zhou J
Pharmacol Rep; 2018 Oct; 70(5):908-916. PubMed ID: 30099297
[TBL] [Abstract][Full Text] [Related]
3. mTOR inhibition of cardamonin on antiproliferation of A549 cells is involved in a FKBP12 independent fashion.
Tang Y; Fang Q; Shi D; Niu P; Chen Y; Deng J
Life Sci; 2014 Mar; 99(1-2):44-51. PubMed ID: 24508654
[TBL] [Abstract][Full Text] [Related]
4. Cardamonin Inhibits Metastasis of Lewis Lung Carcinoma Cells by Decreasing mTOR Activity.
Niu PG; Zhang YX; Shi DH; Liu Y; Chen YY; Deng J
PLoS One; 2015; 10(5):e0127778. PubMed ID: 25996501
[TBL] [Abstract][Full Text] [Related]
5. Antiproliferation of cardamonin is involved in mTOR on aortic smooth muscle cells in high fructose-induced insulin resistance rats.
Liao Q; Shi DH; Zheng W; Xu XJ; Yu YH
Eur J Pharmacol; 2010 Sep; 641(2-3):179-86. PubMed ID: 20566415
[TBL] [Abstract][Full Text] [Related]
6. Anti-inflammatory Effects of Cardamonin in Ovarian Cancer Cells Are Mediated via mTOR Suppression.
Chen H; Shi D; Niu P; Zhu Y; Zhou J
Planta Med; 2018 Nov; 84(16):1183-1190. PubMed ID: 29772587
[TBL] [Abstract][Full Text] [Related]
7. Cardamonin ameliorates insulin resistance induced by high insulin and high glucose through the mTOR and signal pathway.
Niu P; Zhang Y; Shi D; Chen Y; Deng J
Planta Med; 2013 Apr; 79(6):452-8. PubMed ID: 23512499
[TBL] [Abstract][Full Text] [Related]
8. Raptor mediates the selective inhibitory effect of cardamonin on RRAGC-mutant B cell lymphoma.
Liu Y; Zhu Y; Chen H; Zhou J; Niu P; Shi D
BMC Complement Med Ther; 2023 Sep; 23(1):336. PubMed ID: 37749558
[TBL] [Abstract][Full Text] [Related]
9. Raptor mediates the antiproliferation of cardamonin by mTORC1 inhibition in SKOV3 cells.
Shi D; Zhu Y; Niu P; Zhou J; Chen H
Onco Targets Ther; 2018; 11():757-767. PubMed ID: 29445291
[TBL] [Abstract][Full Text] [Related]
10. A novel semisynthetic inhibitor of the FRB domain of mammalian target of rapamycin blocks proliferation and triggers apoptosis in chemoresistant prostate cancer cells.
Morad SA; Schmid M; Büchele B; Siehl HU; El Gafaary M; Lunov O; Syrovets T; Simmet T
Mol Pharmacol; 2013 Feb; 83(2):531-41. PubMed ID: 23208958
[TBL] [Abstract][Full Text] [Related]
11. Cardamonin inhibits the proliferation and metastasis of non-small-cell lung cancer cells by suppressing the PI3K/Akt/mTOR pathway.
Zhou X; Zhou R; Li Q; Jie X; Hong J; Zong Y; Dong X; Zhang S; Li Z; Wu G
Anticancer Drugs; 2019 Mar; 30(3):241-250. PubMed ID: 30640793
[TBL] [Abstract][Full Text] [Related]
12. Potentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell Lines.
Leung EY; Askarian-Amiri M; Finlay GJ; Rewcastle GW; Baguley BC
PLoS One; 2015; 10(7):e0131400. PubMed ID: 26148118
[TBL] [Abstract][Full Text] [Related]
13. Determinants of rapamycin sensitivity in breast cancer cells.
Noh WC; Mondesire WH; Peng J; Jian W; Zhang H; Dong J; Mills GB; Hung MC; Meric-Bernstam F
Clin Cancer Res; 2004 Feb; 10(3):1013-23. PubMed ID: 14871980
[TBL] [Abstract][Full Text] [Related]
14. Cardamonin Inhibits Angiogenesis by mTOR Downregulation in SKOV3 Cells.
Xue ZG; Niu PG; Shi DH; Liu Y; Deng J; Chen YY
Planta Med; 2016 Jan; 82(1-2):70-5. PubMed ID: 26393941
[TBL] [Abstract][Full Text] [Related]
15. New inhibitors of the PI3K-Akt-mTOR pathway: insights into mTOR signaling from a new generation of Tor Kinase Domain Inhibitors (TORKinibs).
Feldman ME; Shokat KM
Curr Top Microbiol Immunol; 2010; 347():241-62. PubMed ID: 20549474
[TBL] [Abstract][Full Text] [Related]
16. Distinct signaling events downstream of mTOR cooperate to mediate the effects of amino acids and insulin on initiation factor 4E-binding proteins.
Wang X; Beugnet A; Murakami M; Yamanaka S; Proud CG
Mol Cell Biol; 2005 Apr; 25(7):2558-72. PubMed ID: 15767663
[TBL] [Abstract][Full Text] [Related]
17. Cardamonin inhibits breast cancer growth by repressing HIF-1α-dependent metabolic reprogramming.
Jin J; Qiu S; Wang P; Liang X; Huang F; Wu H; Zhang B; Zhang W; Tian X; Xu R; Shi H; Wu X
J Exp Clin Cancer Res; 2019 Aug; 38(1):377. PubMed ID: 31455352
[TBL] [Abstract][Full Text] [Related]
18. Cardamonin inhibits cell proliferation by caspase-mediated cleavage of Raptor.
Zhu Y; Zhou J; Niu P; Chen H; Shi D
Naunyn Schmiedebergs Arch Pharmacol; 2021 Apr; 394(4):809-817. PubMed ID: 33043385
[TBL] [Abstract][Full Text] [Related]
19. Potential new therapy of Rapalink-1, a new generation mammalian target of rapamycin inhibitor, against sunitinib-resistant renal cell carcinoma.
Kuroshima K; Yoshino H; Okamura S; Tsuruda M; Osako Y; Sakaguchi T; Sugita S; Tatarano S; Nakagawa M; Enokida H
Cancer Sci; 2020 May; 111(5):1607-1618. PubMed ID: 32232883
[TBL] [Abstract][Full Text] [Related]
20. Synergistic Effects between mTOR Complex 1/2 and Glycolysis Inhibitors in Non-Small-Cell Lung Carcinoma Cells.
Jiang S; Zou Z; Nie P; Wen R; Xiao Y; Tang J
PLoS One; 2015; 10(7):e0132880. PubMed ID: 26176608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
